Paper Details

  1. Home
  2. Paper Details

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.

Author: HeinrichMichael C, KampaKerstin M, SchittenhelmMarcus M, YeeKevin W H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Tandutinib, a FLT3 inhibitor, demonstrates synergistic anti-leukemic effects when combined with standard chemotherapy for acute myeloid leukemia (AML), particularly in patients with FLT3 internal tandem duplications (ITD).
Paper Details　
Original Abstract of the Article :
AML remains a difficult disease to treat. Despite response to induction chemotherapy, most patients ultimately relapse. Further, among elderly patients, aggressive therapy options are often limited due to other medical conditions and decreased tolerance of these patients to conventional chemotherapy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4161/cc.8.16.9355

データ提供：米国国立医学図書館（NLM）

Tandutinib: A Promising New Weapon in the Battle Against AML

Acute myeloid leukemia (AML) is a challenging disease to treat, but this study investigates the potential of a new FLT3 inhibitor, tandutinib, in combination with standard chemotherapy agents. The authors explore the synergistic effects of tandutinib with cytarabine and daunorubicin, aiming to improve treatment outcomes for AML patients, particularly those with FLT3 internal tandem duplications (ITD).

Synergy in Action: Tandutinib's Potential to Enhance AML Treatment

The study demonstrates that tandutinib, when combined with standard chemotherapy, exhibits synergistic antileukemic effects, particularly in FLT3 ITD-positive patients. This finding suggests that tandutinib could be a valuable addition to the treatment arsenal for AML.

Hope for AML Patients: Exploring New Treatment Options

The study offers a ray of hope for patients with AML, especially those with FLT3 ITD mutations. The potential for tandutinib to enhance the effectiveness of chemotherapy and potentially reduce side effects makes it a promising candidate for future clinical trials.

Dr.Camel's Conclusion

This research is like finding a new oasis in the desert of AML research, offering a promising new path forward for treating this challenging disease. Tandutinib, like a cool breeze in the desert, has the potential to invigorate the fight against AML, offering hope to patients facing this difficult diagnosis.

Date :
  1. Date Completed 2009-10-27
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

19625780

DOI: Digital Object Identifier

10.4161/cc.8.16.9355

Related Literature

Article Analysis
・Effects of daunorubicin・Effects of cytarabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.